Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have been diagnosed with Acute Myeloblastic Leukaemia (a type of blood cancer), confirmed through laboratory testing, and classified according to the ELN 2022 guidelines
• People who are about to start treatment with a combination of two medicines — venetoclax and azacitidine — for the first time (note: adding a third targeted medicine to this combination is not permitted in this trial)
• People who are willing and able to read, understand, and sign a voluntary consent form before any trial procedures begin
• People who are enrolled in, or covered by, a social security system

Who may not be able to join:

• People diagnosed with a specific subtype of leukaemia called acute promyelocytic leukaemia (APL, also known as AML3)
• People whose leukaemia is considered suitable for intensive chemotherapy
• People who have previously been treated with venetoclax and/or azacitidine
• People who are currently taking part in another clinical trial involving a medicinal product
• People who have a condition that would make the blood collection procedures required by the trial unsafe or not possible
• People whose psychological, family, geographical, or social circumstances, in the opinion of the trial investigator, could affect their ability to sign a consent form or follow the trial procedures
• People who are under a legal protection arrangement such as curatorship, guardianship, or judicial protection
• People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.